DNA vaccines for autoimmune diseases

References

• Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 899–910 (2006).
   PubMed Web of Science ®Google Scholar
• Stuve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. a4-integrin antagonism with natalizumab: effects and adverse effects. J. Neurol.255(Suppl. 6), 58–65 (2008).
   PubMed Web of Science ®Google Scholar
• Pietropaolo M, Eisenbarth GS. Autoantibodies in human diabetes. Curr. Dir. Autoimmun.4, 252–282 (2001).
   PubMedGoogle Scholar
• Pietropaolo M, Surhigh JM, Nelson PW, Eisenbarth GS. Primer: immunity and autoimmunity. Diabetes57(11), 2872–2882 (2008).
   Google Scholar
• Kent SC, Chen Y, Bregoli L et al. Expanded T cells from pancreatic lymph nodes of Type 1 diabetic subjects recognize an insulin epitope. Nature435(7039), 224–228 (2005).
   PubMed Web of Science ®Google Scholar
• Weiner HL, Mackin GA, Matsui M et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science259(5099), 1321–1324 (1993).
   PubMed Web of Science ®Google Scholar
• Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H. Oral administration of myelin induces antigen-specific TGF-b1 secreting T cells in patients with multiple sclerosis. Ann. NY Acad. Sci.835, 120–131 (1997).
   PubMed Web of Science ®Google Scholar
• Faria AM, Weiner HL. Oral tolerance. Immunol. Rev.206, 232–259 (2005).
   PubMed Web of Science ®Google Scholar
• Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur. J. Neurol.13(8), 887–895 (2006).
   PubMed Web of Science ®Google Scholar
• Warren KG, Catz I, Wucherpfennig KW. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J. Neurol. Sci.152(1), 31–38 (1997).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat. Med.6(10), 1167–1175 (2000).
   PubMed Web of Science ®Google Scholar
• Kappos L, Comi G, Panitch H et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med.6(10), 1176–1182 (2000).
   PubMed Web of Science ®Google Scholar
• Mitchison NA. Induction of immunological paralysis in two zones of dosage. Proc. R. Soc. Lond. B Biol. Sci.161, 275–292 (1964).
   PubMed Web of Science ®Google Scholar
• Kamradt T, Mitchison NA. Tolerance and autoimmunity. N. Engl. J. Med.344(9), 655–664 (2001).
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin. Immunol.12(3), 163–171 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrera F, La Cava A, Rizzi M, Hahn BH, Indiveri F, Filaci G. Gene vaccination for the induction of immune tolerance. Ann. NY Acad. Sci.1110, 99–111 (2007).
   PubMed Web of Science ®Google Scholar
• Fontoura P, Garren H, Steinman L. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int. Rev. Immunol.24(5–6), 415–446 (2005).
   PubMed Web of Science ®Google Scholar
• Prud’homme GJ, Draghia-Akli R, Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther.14(7), 553–564 (2007).
   PubMed Web of Science ®Google Scholar
• Delavallee L, Assier E, Denys A et al. Vaccination with cytokines in autoimmune diseases. Ann. Med.40(5), 343–351 (2008).
   PubMed Web of Science ®Google Scholar
• Waisman A, Ruiz PJ, Hirschberg DL et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat. Med.2(8), 899–905 (1996).
   PubMed Web of Science ®Google Scholar
• O’Garra A, Steinman L, Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr. Opin. Immunol.9(6), 872–883 (1997).
   PubMed Web of Science ®Google Scholar
• Lobell A, Weissert R, Storch MK et al. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med.187(9), 1543–1548 (1998).
   PubMed Web of Science ®Google Scholar
• Lobell A, Weissert R, Eltayeb S et al. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J. Immunol.170(4), 1806–1813 (2003).
   PubMed Web of Science ®Google Scholar
• Wefer J, Harris RA, Lobell A. Protective DNA vaccination against experimental autoimmune encephalomyelitis is associated with induction of IFNb. J. Neuroimmunol.149(1–2), 66–76 (2004).
   PubMed Web of Science ®Google Scholar
• Andersson A, Isaksson M, Wefer J et al. Impaired autoimmune T helper 17 cell responses following DNA vaccination against rat experimental autoimmune encephalomyelitis. PLoS ONE3(11), e3682 (2008).
   Google Scholar
• Tsunoda I, Kuang LQ, Tolley ND, Whitton JL, Fujinami RS. Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. J. Neuropathol. Exp. Neurol.57(8), 758–767 (1998).
   PubMed Web of Science ®Google Scholar
• Ruiz P, Garren H, Urbanek-Ruiz I et al. Suppressive immunization with DNA encoding a self-protein prevents autoimmune disease: modulation of T cell costimulation. J. Immunol.162, 3336–3341 (1999).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T et al.A Toll-like receptor recognizes bacterial DNA. Nature408(6813), 740–745 (2000).
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374(6522), 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• Lobell A, Weissert R, Eltayeb S, Svanholm C, Olsson T, Wigzell H. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis. J. Immunol.163(9), 4754–4762 (1999).
   PubMed Web of Science ®Google Scholar
• Ho PP, Fontoura P, Ruiz PJ, Steinman L, Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J. Immunol.171(9), 4920–4926 (2003).
   PubMed Web of Science ®Google Scholar
• Ho PP, Fontoura P, Platten M et al. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. J. Immunol.175(9), 6226–6234 (2005).
   PubMed Web of Science ®Google Scholar
• Garren H. A DNA vaccine for multiple sclerosis. Expert Opin. Biol. Ther.8(10), 1539–1550 (2008).
   PubMed Web of Science ®Google Scholar
• Wiest-Ladenburger U, Fortnagel A, Richter W, Reimann J, Boehm BO. DNA vaccination with glutamic acid decarboxylase (GAD) generates a strong humoral immune response in BALB/c, C57BL/6, and in diabetes- prone NOD mice. Horm. Metab. Res.30(10), 605–609 (1998).
   Google Scholar
• Filippova M, Liu J, Escher A. Effects of plasmid DNA injection on cyclophosphamide-accelerated diabetes in NOD mice. DNA Cell Biol.20(3), 175–181 (2001).
   PubMed Web of Science ®Google Scholar
• Balasa B, Boehm BO, Fortnagel A et al. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. Clin. Immunol.99(2), 241–252 (2001).
   PubMed Web of Science ®Google Scholar
• Li AF, Escher A. Intradermal or oral delivery of GAD-encoding genetic vaccines suppresses Type 1 diabetes. DNA Cell Biol.22(4), 227–232 (2003).
   PubMed Web of Science ®Google Scholar
• Goudy KS, Wang B, Tisch R. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of Type 1 diabetes in nonobese diabetic mice. Clin. Immunol.129(1), 49–57 (2008).
   PubMed Web of Science ®Google Scholar
• Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J. Clin. Invest.104(2), 189–194 (1999).
   PubMed Web of Science ®Google Scholar
• Urbanek-Ruiz I, Ruiz PJ, Paragas V, Garren H, Steinman L, Fathman CG. Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clin. Immunol.100(2), 164–171 (2001).
   PubMed Web of Science ®Google Scholar
• Bot A, Smith D, Bot S et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol.167(5), 2950–2955 (2001).
   PubMed Web of Science ®Google Scholar
• Weaver DJ Jr, Liu B, Tisch R. Plasmid DNAs encoding insulin and glutamic acid decarboxylase 65 have distinct effects on the progression of autoimmune diabetes in nonobese diabetic mice. J. Immunol.167(1), 586–592 (2001).
   PubMed Web of Science ®Google Scholar
• Tisch R, Wang B, Weaver DJ et al. Antigen-specific mediated suppression of b cell autoimmunity by plasmid DNA vaccination. J. Immunol.166(3), 2122–2132 (2001).
   PubMed Web of Science ®Google Scholar
• Wolfe T, Bot A, Hughes A et al. Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent Type 1 diabetes: addition of IL-4 increases safety. Eur. J. Immunol.32(1), 113–121 (2002).
   PubMed Web of Science ®Google Scholar
• Li AF, Hough J, Henderson D, Escher A. Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in mice. Vaccine22(13–14), 1751–1763 (2004).
   PubMed Web of Science ®Google Scholar
• Solvason N, Lou YP, Peters W et al. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J. Immunol.181(12), 8298–8307 (2008).
   PubMed Web of Science ®Google Scholar
• Ragno S, Colston MJ, Lowrie DB, Winrow VR, Blake DR, Tascon R. Protection of rats from adjuvant arthritis by immunization with naked DNA encoding for mycobacterial heat shock protein 65. Arthritis Rheum.40(2), 277–283 (1997).
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Carmi P, Mor F, Cohen IR. Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60. J. Immunol.169(6), 3422–3428 (2002).
   PubMed Web of Science ®Google Scholar
• Santos-Junior RR, Sartori A, De Franco M et al.Immunomodulation and protection induced by DNA–hsp65 vaccination in an animal model of arthritis. Hum. Gene Ther.16(11), 1338–1345 (2005).
   PubMedGoogle Scholar
• Ho PP, Higgins JP, Kidd BA et al. Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity39(8), 675–682 (2006).
   PubMed Web of Science ®Google Scholar
• Song X, Liang F, Liu N et al. Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine27(5), 690–700 (2009).
   Google Scholar
• Silver PB, Agarwal RK, Su SB et al. Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J. Immunol.179(8), 5146–5158 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrera F, Hahn BH, Rizzi M et al. Protection against renal disease in (NZB × NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. Arthritis Rheum.56(6), 1945–1953 (2007).
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Vollmer T, Antel J et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled Phase 1/2 trial. Arch. Neurol.64(10), 1407–1415 (2007).
   PubMed Web of Science ®Google Scholar
• Garren H, Robinson WH, Krasulova E et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann. Neurol.63(5), 611–620 (2008).
   PubMed Web of Science ®Google Scholar
• Palmer JP, Fleming GA, Greenbaum CJ et al. C-peptide is the appropriate outcome measure for Type 1 diabetes clinical trials to preserve b-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes53(1), 250–264 (2004).
   PubMedGoogle Scholar
• Herold KC, Gitelman SE, Masharani U et al. A single course of anti-CD3 monoclonal antibody hOKT3g1(Ala–Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes54(6), 1763–1769 (2005).
   PubMed Web of Science ®Google Scholar
• Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N. Engl. J. Med.346(22), 1692–1698 (2002).
   PubMed Web of Science ®Google Scholar
• Agardh CD, Cilio CM, Lethagen A et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Complicat.19(4), 238–246 (2005).
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med.352(25), 2598–2608 (2005).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today13(1), 11–16 (1992).
   PubMedGoogle Scholar
• Robinson WH, Fontoura P, Lee BJ et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol.21(9), 1033–1039 (2003).
   PubMed Web of Science ®Google Scholar
• Garren H, King R, Quan J et al.; BHT-3009 Study Group. One year follow-up results from a Phase 2 trial of the BHT-3009 DNA vaccine for multiple sclerosis. Presented at: American Academy of Neurology Annual Meeting. Seattle, WA, USA, 30 April 2009.
   Google Scholar
• Gottlieb P, Colman P, Kipnes M et al.Interim results of a Phase I/II clinical trial of a DNA plasmid vaccine (BHT-3021) for Type 1 diabetes. Presented at: American Diabetes Association, 69th Scientific Sessions. New Orleans, LA, USA, 6 June 2009.
   Google Scholar